UCB Commitment to Addressing Real World Patient Needs on Display at the Annual European Congress of Rheumatology (EULAR

11. [SAT0389]: Long-Term Improvements in Workplace and Household Productivity and Social Participation over 4 Years of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis   van der Heijde, D. et al.   

- Date/Time: Saturday 11 June, 10:15 - 12:00
- Session Info: Spondyloarthritis - treatment; Poster area (poster presentation)

12. [THU0380]: A Single Determination of C-Reactive Protein Does Not Suffice to Declare a Patient with a Diagnosis of Axial SpA 'CRP-Negative'   Landewé, R. et al.   

- Date/Time: Thursday 9 June, 11:50
- Session Info: Axial SpA: Clinical aspects; Poster area (poster presentation and poster
tour)

Presentations on Cimzia(R) in Psoriatic Arthritis   

13. [FRI0471]: Certolizumab Pegol for the Treatment of Psoriatic Arthritis: 4-Year Outcomes from the RAPID-PsA Trial   Mease, P.J. et al.   

- Date/Time: Friday 10 June, 11:45 - 13:30
- Session Info: Psoriatic arthritis; Poster area (poster presentation)

14. [FRI0472]: Improvements in Joint Outcomes of Psoriatic Arthritis over 4 Years of Treatment with Certolizumab Pegol in Patients with and without Prior Anti-TNF Exposure   Mease, P.J. et al.   

- Date/Time: Friday 10 June, 11:45 - 13:30
- Session Info: Psoriatic arthritis; Poster area (poster presentation)

Presentations on Cimzia(R) Across Indications   

15. [THU0620]: Gender, Disease Activity, Anxiety and Depression Levels Are Related to the Levels of Fears of Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Cross-Sectional Study of 672 Patients   Gossec, L. et al.   

- Date/Time: Thursday June 9, 11:45 - 13:30
- Session Info: Epidemiology, health services and outcome research; Poster area (poster
presentation)

16. [THU0619]: Lifestyle Beliefs of 672 Patients with Rheumatoid Arthritis or Axial Spondyloarthritis   Gossec, L. et al.   

- Date/Time: Thursday June 9, 11:45 - 13:30
- Session Info: Epidemiology, health services and outcome research; Poster area (poster
presentation)

Presentations on Cimzia(R) Safety   

17. [THU0136]: Use of a Global Risk Score to Identify Patients with Rheumatoid Arthritis at Risk of Serious Infectious Events During Certolizumab Pegol Treatment   Curtis, J.R. et al.   

- Date/Time: Thursday 9 June, 11:45 - 13:30
- Session Info: Rheumatoid arthritis - anti-TNF therapy; Poster area (poster
presentation)

Presentation on Bimekizumab in Psoriatic Arthritis   

18. [OP0108]: Bimekizumab, a Monoclonal Antibody that Inhibits Both IL-17A and IL-17F, Produces a Profound Response in Both Skin and Joints: Results of an Early-Phase, Proof-of-Concept Study in Psoriatic Arthritis  Glatt, S. et al.   

- Date/Time: Friday 10 June, 10:20
- Session Info: Expanding therapeutic options in spondyloarthritis; Hall B (oral
presentation)

Presentation on Dapirolizumab Pegol    

19. [OP0040]: Peripheral Blood Transcriptional Changes Elicited by Treatment of Systemic Lupus Erythematosus (SLE) Patients with Dapirolizumab Pegol (a Pegylated Anti-CD40L Fab')   Ranger, A. et al.   

- Date/Time: Thursday 9 June, 10:30
- Session Info: Advances in SLE Therapeutics; Hall D (oral presentation)

Presentation on Romosozumab   

20. [OP0100]: Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared With Teriparatide in Women With Postmenopausal Osteoporosis Transitioning From Bisphosphonate Therapy: Results of the Phase 3 Open-label STRUCTURE Study  Langdahl, B. et al.   

- Date/Time: Thursday 9 June, 10:20
- Session Info: Clinical Osteoporosis: new insights; Capital Suite 02 (oral presentation)

About Romosozumab    

Romosozumab is an investigational bone-forming monoclonal antibody and is not approved by any regulatory authority for the treatment of osteoporosis. It is designed to work by inhibiting the protein sclerostin, and has a dual effect on bone, both increasing bone formation and decreasing bone resorption. Romosozumab is being studied for its potential to reduce the risk of fractures in an extensive global Phase 3 program. This program includes two large fracture trials comparing romosozumab to either placebo or active comparator in more than 10,000 postmenopausal women with osteoporosis. Amgen and UCB are co-developing romosozumab.

About Bimekizumab    

Bimekizumab is an investigational monoclonal antibody specifically designed to potently and selectively inhibit the biological function of both IL-17A and IL-17F, two key pro-inflammatory cytokines. IL-17A and IL-17F are involved in chronic inflammatory processes that drive many severe skin and joint diseases. It is planned that dose-ranging studies for bimekizumab will start this year. Bimekizumab is not approved by any regulatory authority worldwide.

About Dapirolizumab Pegol   

Dapirolizumab pegol (CDP7657) is an anti-CD40L pegylated Fab' being developed in systemic lupus erythematosus (SLE) jointly with Biogen, and has completed a clinical Phase 1b study at the end of 2014. The compound is scheduled to progress to Phase 2 in 2016 and is not approved by any regulatory authority worldwide.

About Cimzia in the EU/EEA In the EU, Cimzia in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying anti-rheumatic drugs (DMARDs) including MTX.

Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. Cimzia in combination with MTX is also indicated for the treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.

Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.

Cimzia, in combination with MTX, is also indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Cimzia is also indicated in the EU for the treatment of adult patients with severe active axial spondyloarthritis (axSpA), comprising:

- Ankylosing spondylitis (AS) - adults with severe active AS who have had an
inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs
(NSAIDs).
- Axial spondyloarthritis (axSpA) without radiographic evidence of AS - adults with
severe active axSpA without radiographic evidence of AS but with objective signs of
inflammation by elevated C-reactive protein (CRP) and/or Magnetic Resonance Imaging
(MRI) who have had an inadequate response to, or are intolerant to NSAIDs.

(CONTINUA)